Oliver Boix
4PUBLICATIONS
15CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Jan 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.Jennifer R Diamond, Valentina Boni, Emerson Lim
|Sep 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.Florence Atrafi, Oliver Boix, Vivek Subbiah
|Nov 11, 2020
Pasotuxizumab, a BiTE<sup>®</sup> immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich
|Dec 15, 2019
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.Andreas Schneeweiss, Dagmar Hess, Markus Joerger
Pageof 1
Frequent Collaborators
1 joint publications
Markus Joerger
1 joint publications
Andrea Varga
1 joint publications
Gary Wilkinson
1 joint publications
Matthias Ocker
1 joint publications
Manik Chatterjee
1 joint publications
Andreas Buck
1 joint publications
Bülent Polat
1 joint publications
Ralf C Bargou
1 joint publications
Vivek Subbiah
1 joint publications
Ron H J Mathijssen
